Scientists at Nanyang Technological University in Singapore have identified three distinct vulnerabilities in bacteria that resist standard antibiotics, according to a series of studies published in October 2026. The research teams developed a compound that blocks energy production in one resistant bacterium, uncovered how another evades viral attacks, and mapped the molecular structure of a toxin-delivery weapon used by a third pathogen. Together, the findings open new routes for treatments that could sidestep the growing threat of antimicrobial resistance, which the World Health Organization estimates will cause 10 million deaths annually by 2050 if left unchecked.
One team, led by Professor Gerhard Grüber of NTU's School of Biological Sciences, created a compound that inhibits a crucial enzyme in Mycobacterium abscessus, a bacterium that causes severe lung disease in cystic fibrosis patients and resists many common antibiotics. Using cryo-electron microscopy, the researchers pinpointed a pocket in the cytochrome b subunit of the bacterium's cytochrome bcc oxidase, an enzyme essential to its electron transport chain. The compound they designed fits into that pocket and stops the enzyme from functioning. Because the structure is unique to M. abscessus, the compound doesn't harm human cells. When paired with clofazimine, an antibiotic used for mycobacterial infections, the new compound achieved a 2-log fold reduction in M. abscessus bacteria within four days. A patent has been filed, and the team is collaborating with U.S. pharmaceutical company Hsiri Therapeutics to license the molecule. In a separate study published in the Proceedings of the National Academy of Sciences, NTU researchers working with Singapore's Agency for Science, Technology and Research discovered how M. abscessus resists bacteriophages—viruses that infect bacteria and hijack their replication machinery. The bacterium exists in two forms: smooth, which produces surface lipids called glycopeptidolipids, and rough, which lacks those lipids and causes more severe, harder-to-treat disease. When the scientists treated smooth strains with bacteriophages, rough variants emerged with mutations in genes coding for enzymes needed to make and transport glycopeptidolipids. The researchers believe losing these lipids prevents phages from binding to the bacteria.
"As the currency of life, ATP delivers the energy for essential processes in M. abscessus, including its defense mechanisms against antibiotics," Grüber explained. "Silencing the electron transport chain that produces ATP is thus a potential treatment for difficult-to-treat M. abscessus infections that also disables the bacterium." Professor Pablo Bifani of NTU's Lee Kong Chian School of Medicine, who led the phage resistance study, noted that "although phages can effectively eliminate bacteria, they may also inadvertently make infections more difficult to treat." He suggested that using a cocktail of bacteriophages targeting both smooth and rough variants might reduce the likelihood of resistance developing. Meanwhile, researchers at NTU and Imperial College London mapped the structure of the Type VI Secretion System in Pseudomonas aeruginosa, another highly resistant pathogen. The system works like a speargun, injecting toxins into rival bacteria and host immune cells to help the bacterium colonize its host.
The studies reveal that resistant bacteria depend on specific molecular machinery that can be disrupted. The compound targeting M. abscessus works because the bacterium relies on ATP—produced by the electron transport chain—to power both its survival and its antibiotic defense systems. Blocking that energy source essentially disarms the bacterium. The phage resistance findings highlight a challenge: while viruses can kill bacteria, they may inadvertently select for more dangerous variants. The rough form of M. abscessus is harder to treat than the smooth form, so phage therapy could backfire unless multiple viral strains are used simultaneously. The P. aeruginosa research shows that the bacterium doesn't fire a single toxin but loads multiple toxins into its secretion system by first wrapping them in ring-shaped protein complexes called Hcp, which stack to form a tube. When the system contracts, it propels the tube outward, delivering a cocktail of toxins in one strike.
Looking ahead, the researchers say blocking the toxin-loading step in P. aeruginosa could lead to approaches that disarm the bacterium and make it less able to cause disease. They also suggest that harmless bacteria could be engineered with a toxin-loaded secretion system to fight antimicrobial-resistant gut pathogens. For M. abscessus, combining the ATP-blocking compound with existing antibiotics may offer a path to treating infections that are currently nearly impossible to cure. The work underscores a broader shift in strategy: instead of developing new antibiotics that bacteria will eventually resist, scientists are targeting the molecular machinery that resistant bacteria need to survive, defend themselves, and spread.